Watchlist Price Alert

Bioventus Inc. (BVS)

NASDAQ: BVS · Real-Time Price · USD

6.70

-0.10 (-1.47%)

At close: May 09, 2025, 3:59 PM

6.47

-3.36%

After-hours: May 09, 2025, 04:10 PM EDT

-1.47% (1D)

Bid	6.08
Market Cap	444.26M
Revenue (ttm)	573.28M
Net Income (ttm)	-33.54M
EPS (ttm)	-0.52
PE Ratio (ttm)	-12.87
Forward PE	7.88
Analyst	Buy

Ask	8
Volume	417,644
Avg. Volume (20D)	384,921
Open	6.79
Previous Close	6.80
Day's Range	6.66 - 6.90
52-Week Range	4.51 - 14.38
Beta	0.95

About BVS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BVS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for BVS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Bioventus has released their quartely earnings on May 6, 2025:

Revenue of $123.88M exceeds estimates by $1.17M, with -4.31% YoY decline.

EPS of 0.08 exceeds estimates by 0.06, with 14.29% YoY growth.

Why Price Moved

6 days ago

-11.81%

Bioventus shares are trading lower following Q1 re... Unlock content with Pro Subscription

2 months ago

+23.29%

Bioventus shares are trading higher after the company reported better-than-expected Q4 financial results.

News

6 days ago · seekingalpha.com

Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript

Bioventus Inc. (NASDAQ:BVS ) Q1 2025 Results Conference Call May 6, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Sin...

6 days ago · zacks.com

Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates

Bioventus (BVS) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago.

3 weeks ago · zacks.com

4 Healthcare Stocks to Buy as the Sector Faces Government Heat

Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.

1 month ago · zacks.com

Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now

Bioventus (BVS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a tr...

1 month ago · zacks.com

Bioventus (BVS) Upgraded to Buy: Here's What You Should Know

Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago · seekingalpha.com

Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript

Bioventus Inc. (NASDAQ:BVS ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark...

2 months ago · benzinga.com

Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million

On Tuesday, Bioventus Inc. BVS reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents.

2 months ago · zacks.com

Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates

Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.